-
Mashup Score: 0Reply to “Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era” - 3 year(s) ago
It is exciting to see that IL-5 receptor alpha (IL-5Rα) blockade (benralizumab) is gaining interest as a therapy for drug rash with eosinophilia and systemic symptoms (DRESS) in the setting of severe acute respiratory syndrome coronavirus 2 infection. In the most recent report by Mesli et al1 and our previous article,2 patients with severe acute respiratory syndrome coronavirus 2 infection had…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era - 3 year(s) ago
We read with great interest the article by Schmid-Grendelmeier et al1 who reported on IL-5Rα blockade with benralizumab in 2 patients with coronavirus disease 2019 (COVID-19) with refractory drug rash with eosinophilia and systemic symptoms (DRESS), and would like to share our experience of a similar case successfully treated with benralizumab.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3Recurrent cardiac arrest due to eosinophilia-related coronary vasospasm successfully treated by benralizumab - 3 year(s) ago
Eosinophil-related cardiovascular toxicity mostly consists of endomyocardial fibrosis, endocardial thrombi (with subsequent potential cardiac embolism), venous thromboembolism, and eosinophilic vasculitis.1,2 Eosinophilia-related coronary vasospasm is a rare and underrecognized life-threatening condition that has been reported in patients with aspirin-exacerbated respiratory disease (AERD),…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) affects around 60% of patients with Severe Eosinophilic Asthma (SEA). Benralizumab was recently approved for SEA add-on treatment.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
Article InfoPublication HistoryAccepted: July 22, 2021Received in revised form: June 26, 2021Received: May 27, 2021Publication stageIn Press Journal Pre-ProofFootnotesConflicts of Interest:IB,AFB,PM: no conflicts of interest.FH: Speaker fees from Brainlab, Spiggle&Theiss.NK:Speaker fees from Astrazeneca.KM: Speaker fees from…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Reply to Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era - 3 year(s) ago
Lang Claudia Cécile Valérie, MD Lang Claudia Cécile ValérieAffiliationsFaculty of Medicine, University of Zurich, Zurich, SwitzerlandDepartment of Dermatology, University Hospital Zurich, Zurich, SwitzerlandSchmid-Grendelmeier Peter, MD Schmid-Grendelmeier PeterAffiliationsFaculty of Medicine, University of Zurich, Zurich, SwitzerlandDepartment of Dermatology, University Hospital Zurich, Zurich,…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 4Benralizumab: a potential tailored treatment for life-threatening DRESS in the COVID-19 era - 3 year(s) ago
Farah Mesli, MD Farah MesliAffiliationsMédecine Intensive Réanimation, Hôpital Tenon (Assistance Publique-Hôpitaux de Paris), Paris, France. Sorbonne Université, Paris, FranceMaëlle Dumont, MD Maëlle DumontAffiliationsService de Dermatologie et d’Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France Sorbonne Universités Paris, Centre d’Immunologie et des Maladies Infectieuses – Paris…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Recurrent cardiac arrest due to eosinophilia-related coronary vasospasm successfully treated by benralizumab - 3 year(s) ago
Matthieu Groh, MD, MSc Matthieu GrohCorrespondenceCorresponding author Matthieu Groh, Department of Internal medicine, National Reference Center for Hypereosinophilic Syndromes (CEREO), Hôpital Foch, 40, rue Worth, 92151 Suresnes Cedex, France; ; Phone: +33 146253100; Fax: +33 146252620AffiliationsNational Reference Center…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 6The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma - 3 year(s) ago
Monoclonal antibodies (mAbs) directed against type 2 (T2) inflammatory pathway have revolutionized the treatment of severe eosinophilic asthma (SEA) by improving symptom control and exacerbation frequency, and reducing exposure to oral corticosteroids (OCSs).1,2 Mepolizumab1 and benralizumab2 target IL-5 and IL-5 receptor-alpha (IL-5R), respectively, inhibiting the eosinophilic inflammatory…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Benralizumab Improves Symptoms of Patients with Severe, Eosinophilic Asthma with a Diagnosis of Nasal Polyposis - PubMed - 3 year(s) ago
These substudy data from ANDHI demonstratedthe efficacyprofile of benralizumab for patients with severe, eosinophilic asthma and NP, withimprovement in SNOT-22 and asthma outcomes.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
In Current Issue (Free)! Reply to “ #Benralizumab: A potential tailored treatment for life-threatening #DRESS in the #COVID-19 era” https://t.co/27DrdmglJD